Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Meningioma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoid Tumor 2Prostatic Neoplasms 1Neuroblastoma 1Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Disease 1Carcinoma, Medullary 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

Blood Specimen Collection 9Surveys and Questionnaires 5Magnetic Resonance Spectroscopy 5Biopsy 5Prednisone 4Colonoscopy 4Biopsy, Fine-Needle 4Tomography, X-Ray Computed 3Surgical Procedures, Operative 3Mammography 3Magnetic Resonance Imaging 3Liquid Biopsy 3Lenalidomide 3Interviews as Topic 3Exercise 3Diagnostic Tests, Routine 3Cyclophosphamide 3weifuchun 2pembrolizumab 2obinutuzumab 2Urination 2Preoperative Exercise 2Positron Emission Tomography Computed Tomography 2Observation 2Methods 2Melphalan 2Immunohistochemistry 2Gemcitabine 2Educational Status 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease × Ga(III)-DOTATOC × Clear all
NCT02359500 2017-05-03

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Icahn School of Medicine at Mount Sinai

Phase 1 Terminated
71 enrolled
EndocrineNET

Carcinoid Tumor, Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡